Prof Fred Saad (University of Montreal) drops in to chat about the interesting condition that is non-metastatic castration-resistant prostate cancer (nmCRPC). Which men are at risk of developing metastases? When should we use an AR pathway inhibitor? Why PSMA PET/CT should NOT be used. And hear his thoughts on "dabbling" in prostate cancer! Also joined by Professor Shankar Siva and Dr Louise Kostos from Peter MacCallum Cancer Centre. Hosted as ever by Dr Renu Eapen and Professor Declan Murphy. Fred was on a speaker tour in Australia supported by Bayer Pharmaceuticals and this Themed Podcast is supported by Bayer, Silver Partners of GU Cast.Update  -  we mentioned that darolutamide was the only ARPI listed for reimbursement in Australia (true at time of recording). We can update that all TGA approved ARPIs for nmCRPC are now reimbursed in Australia. Even better on our YouTube channel